Loading
A phase 3 trial of CAIX PET in Clear cell renal cell carcinoma, run by Telix Pharmaceuticals (Innovations) Pty Limited, completed.
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study is a phase 3 interventional study registered as NCT03849118 by Telix Pharmaceuticals (Innovations) Pty Limited, with 300 participants recorded, started 2019-08-15 and reaching its primary completion in 2022-10-20. Interventions recorded: 89Zr-girentuximab. Conditions recorded: Clear Cell Renal Cell Carcinoma.
Linked to the technology CAIX PET because the registry names it ("89zr girentuximab") among its interventions and Clear cell renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Shares CAIX PET (89Zr-girentuximab), Clear cell renal cell carcinoma and the tag pipeline.
Shares Telix Pharmaceuticals and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Telix Pharmaceuticals and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares CAIX PET (89Zr-girentuximab), Telix Pharmaceuticals, Clear cell renal cell carcinoma.